Justin C. Jagodinsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Justin C. Jagodinsky has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Zachary S. Morris
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA
18 shared publications - Paul Alexander Clark
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA
17 shared publications - Won Jong Jin
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA
17 shared publications - Raghava N. Sriramaneni
University of Wisconsin–Madison, Madison, Wisconsin, United States
15 shared publications - Amber M. Bates
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA
13 shared publications - KyungMann Kim
University of Wisconsin–Madison 6 Madison, WI
13 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
B78 WT vs. STING KO cell line in vitro Ifnb1 and Ddx58 gene expression upregulation following 225Ac or EBRT.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
B78 WT vs. STING KO cell line in vitro Ifnb1 and Ddx58 gene expression upregulation following 225Ac or EBRT.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Individual tumor growth curves from Figure 6F.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Individual tumor growth curves from Figure 6F.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Longitudinal in vivo gene expression following 12 Gy EBRT (MOC2).
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Longitudinal in vivo gene expression following 12 Gy EBRT (MOC2).
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Tumor Ifnb1 expression following 225Ac-NM600+ICI is not affected by loss of STING expression in tumor or host.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Tumor Ifnb1 expression following 225Ac-NM600+ICI is not affected by loss of STING expression in tumor or host.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Specific activity maintained in radionuclide-containing cell culture media throughout media exchanges.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Specific activity maintained in radionuclide-containing cell culture media throughout media exchanges.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Representative images of γH2AX foci over time in (A) MOC2 (12 Gy) and (B) B78 (4 Gy) cells following EBRT, 90Y, 177Lu, and 225Ac.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Representative images of γH2AX foci over time in (A) MOC2 (12 Gy) and (B) B78 (4 Gy) cells following EBRT, 90Y, 177Lu, and 225Ac.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Earlier induction of type I IFN response/immunologic response to radiation following 58mCo and 119Sb.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Earlier induction of type I IFN response/immunologic response to radiation following 58mCo and 119Sb.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
90Y-, 177Lu, 225Ac-NM600 modulate tumor immune cell composition in the tumor microenvironment.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
90Y-, 177Lu, 225Ac-NM600 modulate tumor immune cell composition in the tumor microenvironment.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Longitudinal Ifnb1, Mx1, Ddx58, Fas, Pdl1, and Mhc1 expression following (A) 12 Gy EBRT (MOC2) or (B) 4 Gy EBRT (B78) in vitro.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Longitudinal Ifnb1, Mx1, Ddx58, Fas, Pdl1, and Mhc1 expression following (A) 12 Gy EBRT (MOC2) or (B) 4 Gy EBRT (B78) in vitro.